Emergent Stock Insiders

EBS
 Stock
  

USD 20.86  0.28  1.32%   

Emergent Biosolutions employes about 2.4 K people. The company is managed by 21 executives with total tenure of roughly 81 years, averaging almost 3.0 years of service per executive having 115.05 employees per reported executive. Discussion of Emergent Biosolutions management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Emergent Biosolutions future performance.
Continue to Investing Opportunities.
  
  Daniel AbdunNabi  CEO
President CEO, Director
  Fuad ElHibri  Chairman
Executive Chairman of the Board
  Zsolt Harsanyi  Chairman
Non-Executive Independent Chairman of the Board

Emergent Biosolutions Management Team Effectiveness

Emergent Biosolutions has Return on Asset of 6.77 % which means that on every $100 spent on asset, it made $6.77 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 10.17 %, implying that it generated $10.17 on every 100 dollars invested. Emergent Biosolutions management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Emergent Biosolutions Workforce Comparison

Emergent Biosolutions is one of the top stocks in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 34,416. Emergent Biosolutions holds roughly 2,416 in number of employees claiming about 7% of equities under Drug Manufacturers—Specialty & Generic industry.

Emergent Biosolutions Profit Margins

The company has Net Profit Margin of 8.96 %, which may imply that it executes well on its competitive polices and has reasonable control over its expenses and variable costs. This is very large. In the same way, it shows Net Operating Margin of 17.5 %, which entails that for every 100 dollars of revenue, it generated 0.18 of operating income.

Emergent Biosolutions Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Emergent Biosolutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on Emergent Biosolutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Emergent Biosolutions insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Emergent Biosolutions Benchmark Summation

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Indexes of lowest and highest values over a specified period line shows minimum and maximum index of Emergent Biosolutions price series.
.

Emergent Biosolutions Notable Stakeholders

An Emergent Biosolutions stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Emergent Biosolutions often face trade-offs trying to please all of them. Emergent Biosolutions' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Emergent Biosolutions' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel AbdunNabi - President CEO, DirectorProfile
Fuad ElHibri - Executive Chairman of the BoardProfile
Zsolt Harsanyi - Non-Executive Independent Chairman of the BoardProfile
Robert Kramer - CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, TreasurerProfile
Sean Kirk - Executive Vice President - Manufacturing and Technical OperationsProfile
Katherine Strei - Executive Vice President - Human Resources and Communications, Chief Human Resources OfficerProfile
Atul Saran - Executive Vice President Corporate Development, General Counsel and Corporate SecretaryProfile
Adam Havey - Executive VP and President of Biodefense DivisionProfile
Richard Lindahl - Chief Financial Officer, Executive Vice President, TreasurerProfile
Sue Bailey - Independent DirectorProfile
Jerome Hauer - Independent DirectorProfile
Kathryn Zoon - Independent DirectorProfile
Seamus Mulligan - DirectorProfile
George Joulwan - Independent DirectorProfile
Louis Sullivan - Independent DirectorProfile
Ronald Richard - Lead Independent DirectorProfile
Jennifer Fox - Executive Vice President - External Affairs, General Counsel, Corporate SecretaryProfile
Robert Burrows - IR Contact OfficerProfile
Marvin White - DirectorProfile
Karen Smith - Executive Vice President Chief Medical OfficerProfile
Keith Katkin - Independent DirectorProfile

About Emergent Biosolutions Management Performance

The success or failure of an entity such as Emergent Biosolutions often depends on how effective the management is. Emergent Biosolutions management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Emergent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Emergent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.
The data published in Emergent Biosolutions' official financial statements usually reflect Emergent Biosolutions' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Emergent Biosolutions. For example, before you start analyzing numbers published by Emergent accountants, it's critical to develop an understanding of what Emergent Biosolutions' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Emergent Biosolutions' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Emergent Biosolutions' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Emergent Biosolutions' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Emergent Biosolutions. Please utilize our Beneish M Score to check the likelihood of Emergent Biosolutions' management to manipulate its earnings.

Emergent Biosolutions Workforce Analysis

Traditionally, organizations such as Emergent Biosolutions use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Emergent Biosolutions within its industry.

Emergent Biosolutions Manpower Efficiency

Return on Emergent Biosolutions Manpower

Revenue Per Employee728.5 K
Revenue Per Executive83.8 M
Net Income Per Employee65.2 K
Net Income Per Executive7.5 M
Working Capital Per Employee181.2 K
Working Capital Per Executive20.8 M
Continue to Investing Opportunities. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.